Piper Sandler analyst Adam Maeder raised the firm’s price target on Inari Medical (NARI) to $52 from $50 and keeps a Neutral rating on the shares. The firm notes Inari reported record high revenue in Q3 with $153.4M, which topped both consensus and its model. Piper was encouraged to see that the beat was driven by the company’s U.S. core VTE franchise.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NARI: